Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a Phase II safety and efficacy trial

Jimmi Hatton, Pharm.D., Robert P. Rapp, Pharm.D., Kenneth A. Kudsk, M.D., Rex O. Brown, Pharm.D., Mark S. Luer, Pharm.D., Julie G. Bukar, M.B.A., R.D., Sharon A. Chen, Ph.D., Craig J. McClain, M.D., Neil Gesundheit, M.D., Robert J. Dempsey, M.D., and Byron Young, M.D.

College of Pharmacy and the Departments of Surgery and Medicine, University of Kentucky Chandler Medical Center, Lexington, Kentucky; Department of Clinical Pharmacy, College of Pharmacy and Department of Surgery, College of Medicine, University of Tennessee at Memphis, Memphis, Tennessee; and Genentech, Inc., San Francisco, California

The purpose of this study was to determine the effect of insulin-like growth factor-I (IGF-I) on the catabolic state and clinical outcome of head-injured patients. Thirty-three patients between the ages of 18 and 59 years with isolated traumatic head injury and Glasgow Coma Scale (GCS) scores of 4 to 10 were randomized to one of two groups. All patients received standard neurosurgical intensive care plus aggressive nutritional support; the patients in the treatment group also received intravenous therapy with continuous IGF-I (0.01 mg/kg/hour).

During the 14-day dosing period, the control patients lost weight, whereas treated patients gained weight despite a significantly higher measured energy expenditure and lower caloric intake (p = 0.02). Daily glucose concentrations and nitrogen outputs were greater in control patients (p = 0.03) throughout the study period. During Week 1, only treated patients achieved positive nitrogen balance. Fifteen of 17 treated and 13 of 16 control patients survived the 1st week. No deaths occurred in patients whose serum IGF-I concentrations were higher than 350 ng/ml. Dichotomized Glasgow Outcome Scale scores for patients with baseline GCS scores of 5 to 7 improved from poor to good for eight of 12 treated patients but for only three of 11 control patients (p = 0.06). Eight of 11 treated patients with serum IGF-I concentrations that were at least 350 ng/ml achieved moderate-to-good outcome scores at 6 months, compared to only one of five patients with lower concentrations (p < 0.05). These findings indicate that pharmacological concentrations of IGF-I may improve clinical outcome and nitrogen utilization in patients with moderate-to-severe head injury.

Key Words * brain injury * insulin-like growth factor I * nitrogen balance * Glasgow Coma Scale * nutritional support * nutrition * treatment outcome

Patients suffering moderate-to-severe traumatic brain injury (TBI) demonstrate both hypermetabolism (increased energy expenditure) and hypercatabolism (increased protein loss) for up to several months after the insult.\[14,24,47,63\] Many investigators have found it difficult to achieve either positive caloric
Pharmacological strategies to improve the use of nutrients during acute injury are under investigation. Results with growth hormone have been inconsistent, depending on the severity of the injury and the timing of administration. Insulin-like growth factor-I (IGF-I) is believed to mediate many of the anabolic effects of growth hormone. Endogenous concentrations of IGF-I are depressed after brain injury. Severe stress may induce a state of growth hormone resistance, leading to diminished synthesis of IGF-I in response to growth hormone; however, this finding has not been observed by all investigators.

Insulin-like growth factor-I is a neurotrophic factor and has neuroprotective effects. Higher endogenous concentrations of IGF-I are associated with improved survival after TBI. Restoring IGF-I concentrations by administering recombinant human IGF-I (rhIGF-I) after TBI may benefit the patient's neurological response and may also have an effect on the patient's nitrogen balance. The purpose of this investigation was to determine the effect of rhIGF-I on the catabolic state and clinical outcome of patients who have suffered head injury.

CLINICAL MATERIAL AND METHODS

Study Design and Patient Population

This Phase II, open-label, prospective randomized trial was conducted at the University of Kentucky and the University of Tennessee at Memphis. The open-label design was requested by the United States Food and Drug Administration because IGF-I had not previously been administered to patients with TBI. Consecutively admitted patients between the ages of 18 and 59 years who had suffered traumatic head injury and had Glasgow Coma Scale (GCS) scores of 4 to 10 were eligible. Patients were excluded for clinically significant disease or trauma other than head injury, chronic inflammatory diseases, spinal cord injury, diabetes, cancer, or uncontrolled seizures. Those treated by administration of more than 20 mg dexamethasone or its equivalent before randomization, those for whom death appeared to be imminent, and pregnant women were also excluded. After informed consent had been obtained, the patients were randomized on the basis of peak 6-hour postinjury GCS score, steroid dose, and age. All patients received standard neurosurgical intensive care combined with aggressive nutritional support as previously described; the treatment group also received therapy with IGF-I. Intracranial pressure monitors were placed in all patients with GCS scores less than 8, according to routine neurotrauma care. This protocol was approved by the institutional review boards of both universities.

Drug Administration/Monitoring

Insulin-like growth factor-I was provided (Genentech, San Francisco, CA) as a sterile solution containing 5 mg rhIGF-I/1 ml citrate/NaCl, pH 6. The IGF-I was administered by peripheral continuous intravenous infusion at 0.01 mg/kg/hour beginning within 72 hours of injury and continuing for up to 14 days. During the 1st study day, pharmacokinetic sampling of blood was performed at baseline; at 5, 10, 15, 20, 30, 45, 60, and 90 minutes; and at 2, 3, 4, 6, 12, and 24 hours after initiation of the infusion. Serum
concentrations of IGF-I were determined every 24 hours on Days 2 through 13. After the drug was discontinued, blood samples were collected at 0, 5, 10, 15, 20, 30, 45, and 60 minutes and at 2, 2.5, 3, and 4 hours for IGF-I quantification. Samples for determining serum concentrations of IGF-I and binding proteins were collected from control patients every morning. All assays were performed by Genentech.[38] Hematology, blood chemistry, urinalysis, creatinine clearance, partial thromboplastin time, and levels of prothrombin, free thyroxine (T₄), and thyroid-stimulating hormone were assessed regularly throughout the 14-day treatment period and at Day 28.

Nutritional Support
The goal of nutritional support was to provide nonprotein calories equal to 1.25 times the measured energy expenditure (MEE) plus 2 g protein/kg/day for both groups. The MEE was determined by indirect calorimetry. Nonprotein calories were adjusted if the MEE changed by more than 500 calories. The route of nutritional support was not dictated by the protocol. Parenteral nutrition was used until bowel sounds returned and gastric residual volumes were less than 700 ml in 24 hours. Lipid (Intralipid, 20%) provided approximately 30% of nonprotein calories during administration of parenteral nutrition.

Energy expenditure in all patients was measured by indirect calorimetry at baseline and on study Days 2, 3, 4, 6, 8, 10, 12, and 15. Twenty-four hour urine collections were obtained daily through Day 15. Urinary concentrations of nitrogen and 3-methylhistidine (3MH) were analyzed according to their chemiluminescence. Patients were weighed on Days 1, 4, 7, 10, 13, and 15 and at follow-up periods. Anthropometric measurements (triceps skinfold and mid-arm circumference) were recorded on the same schedule as weight.

For patients receiving IGF-I, serum glucose was measured on Day 1 with each pharmacokinetic sample. After the 1st day, serum glucose was monitored by either finger stick or serum concentration every 6 hours. For the control group of patients, glucose monitoring was performed every 12 hours. Serum glucose concentrations were analyzed by using the hexokinase method. Insulin was administered according to a sliding scale protocol when glucose concentrations were greater than 200 mg/dl. Hypoglycemia was defined as a serum glucose concentration of 70 mg/dl or less. Concentrations of C-peptide and insulin concentrations were measured by radioimmunoassay on Days 1 through 15 and on Day 28.

Clinical Outcome
Both GCS scores and intracranial pressures were recorded daily throughout the dosing period. All patients underwent follow-up examinations to assess nutritional and neurological outcome at Day 15, Day 30, the time of hospital discharge, and 3 months and 6 months after injury. Assessments of anthropometrics, weight, GCS score, and Glasgow Outcome Scale[34] (GOS) score were continued throughout this follow-up period.

Statistical Analysis
The metabolic endpoints examined during the study were MEE, nitrogen balance, serum glucose concentration, and urinary excretion of 3MH. These variables were compared between groups by using repeated-measures analysis of covariance with age, GCS score, and prerandomization administration of steroids as covariates. The clinical endpoints were weight, anthropometrics, GCS score, and GOS score at Day 15, Day 28, and 3 months and 6 months postinjury. A linear mixed-effects model for an
unbalanced repeated-measures design was used to compare mean responses between groups for these endpoints.

Calorie and nitrogen variables, laboratory changes, and IGF-I concentrations were compared by using paired and two-sample Student's t-tests. Analysis of documented infections and outcome scores was based on Fisher's exact test for sparse contingency tables and chi-square statistics. Statistical significance was set at $p < 0.05$.

**RESULTS**

*Patient Demographics*

At the two sites, a total of 33 patients were randomized. There were no significant differences in demographic data between the groups (Table 1). Steroids ($< 20$ mg dexamethasone equivalent) were administered to two control patients and to one treated patient before randomization. One patient in the treatment group received 100 mg methylprednisolone as a single dose on study Day 1 for the management of optic neuritis. Fourteen of 17 patients treated with IGF-I completed the 14-day course of therapy. Thirteen of the 16 control patients completed 14 days of the study. Two treated patients and three control patients died during the 14-day dosing period. Therapy was discontinued for a patient in the treatment group because of tachycardia accompanied by persistent agitation. These symptoms continued after discontinuation of the study drug and were not attributed to the IGF-I therapy. All patients received parenteral nutrition as the initial route for nutrition support. Transition to enteral nutrition was accomplished during the 14-day study course for 14 control patients and 13 IGF-I-treated patients. The length of parenteral nutrition compared to enteral nutrition was not different between the groups; most patients received a combination of each as the transition process was applied. The average length of hospital stay was approximately 42 days for survivors in both groups.
Clinical events are summarized in Table 2. No serious life-threatening event was attributed to IGF-I treatment. Patients received standard care for neurosurgical intensive care patients, including courses of antibiotic medications, anticonvulsant agents when required, mannitol, diuretics, and histamine antagonists. No treatment differences were noted between the groups. No differences in vital signs, hematological analyses, or blood chemistry were noted between the groups. Pretreatment free T4 values were within normal limits in both groups. Total pretreatment T4 values were reduced in six of 16 control patients and in nine of 17 IGF-I-treated patients. Pretreatment thyroid-stimulating hormone values were reduced in three treated patients and four control patients. These values returned to normal limits at Day 15, with the exception of total T4 in one IGF-I-treated patient.

| TABLE 1  
CLINICAL CHARACTERISTICS OF 33 HEAD-INJURED PATIENTS |
<table>
<thead>
<tr>
<th>Factor</th>
<th>Control Group (16 patients)</th>
<th>rhIGF-I-Treated Group (17 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>gender (no. of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>female</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>male</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>age (yrs)</td>
<td>27.8 (9.21)</td>
<td>27.6 (7.7)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>median</td>
<td>18–46</td>
<td>18–40</td>
</tr>
<tr>
<td>range</td>
<td>61–115</td>
<td>53–100</td>
</tr>
<tr>
<td>weight at baseline examination (kg)</td>
<td>75.7 (14.89)</td>
<td>71.3 (12.22)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>71.1</td>
<td>68.5</td>
</tr>
<tr>
<td>median</td>
<td>61–115</td>
<td>53–100</td>
</tr>
<tr>
<td>baseline GCS score*</td>
<td>6.1 (2.16)</td>
<td>7 (2.25)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>median</td>
<td>3–10</td>
<td>4–12</td>
</tr>
<tr>
<td>range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>type of head injury (no. of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>closed head injury</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>skull fracture</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>subdural hematoma</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>epidural hematoma</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>intracerebral hematoma</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>intracranial missile</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>elapsed time to treatment (hrs)</td>
<td>57.1 (6.52)</td>
<td>56.5 (9.91)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>54.5</td>
<td>54</td>
</tr>
<tr>
<td>median</td>
<td>41–73</td>
<td>44–73</td>
</tr>
<tr>
<td>range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>time on ventilator (days)</td>
<td>11.4 (5.29)</td>
<td>11.2 (5.86)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>14.5</td>
<td>16</td>
</tr>
<tr>
<td>median</td>
<td>3–16</td>
<td>3–16</td>
</tr>
<tr>
<td>range</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Obtained immediately before administration of first dose.
Nutritional Outcome

Energy Expenditure. Baseline MEEs were $2381 \pm 369$ kcal/day (mean ± standard deviation [SD]) in control patients and $2562 \pm 586$ kcal/day in the treated group. These baseline energy expenditures were from 1 to 1.6 times the predicted energy expenditure in control patients and from 1.1 to 2 times that in treated patients.[32] Overall, control patients had a lower MEE ($p = 0.01$) and higher caloric intake ($p = 0.02$) than patients treated with IGF-I (Fig. 1). The overall average caloric intake was 40 kcal/kg/day in control patients and 36 kcal/kg/day in treated patients. Caloric balance (nonprotein intake minus MEE) was significantly different between the groups (Fig. 1). During both weeks, the control patients had a more positive caloric balance than the treated patients ($p = 0.04$).

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLINICAL EVENTS IN 33 HEAD-INJURED PATIENTS*</td>
</tr>
<tr>
<td>---------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Factor</th>
<th>Control Group (16 patients)</th>
<th>rhIGF-I--Treated Group (17 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICP monitoring (no. of patients)</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>peak ICP values (mm Hg)</td>
<td>$25 \pm 8$</td>
<td>$21 \pm 3.5$</td>
</tr>
<tr>
<td>infections (no. of patients)</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>episodes of pneumonia</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>episodes of bacteremia</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>episodes of urinary tract infection</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>episodes of meningitis</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>decubitus ulcers</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>cellulitis</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>diarrhea</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>diabetes insipidus</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

*ICP = intracranial pressure.
Nonprotein calorie intake was greater in the control group (3260 ± 229 kcal/day [d]) than in the group treated with IGF-I (2576 ± 560 kcal/d; p = 0.02). Measured energy expenditure was higher in the IGF-I group (2908 ± 149 kcal/d) than in the control group (2700 ± 52 kcal/d; p = 0.01).

Nitrogen. The overall mean protein intake was 1.8 ± 0.14 g/kg/day in control patients and 1.6 ± 0.35 g/kg/day in treated patients. Nitrogen intake during Week 1 was not significantly different between the groups; however, during Week 2, intake in the treated group was significantly less than that in the control group (p = 0.002) (Fig. 2). Nitrogen output in the control group was greater than that of the treated group during both study weeks (p = 0.04). The treated group achieved a positive mean nitrogen balance during Week 1 (Fig. 3), but the control group did not. Although nitrogen output was lower in treated patients during Week 2, nitrogen balance was negative in both groups during Week 2. There was no significant difference in 3MH excretion between groups.

Weight. Despite improved caloric balance and higher nitrogen intake, the weight of control patients had
decreased by 2.8 ± 11.1% at Day 15. Conversely, at the same time point, the weight of treated patients had increased by 2.3 ± 8.9% above admission weights. Anthropometric values did not differ significantly between the groups.

Glucose. Average daily glucose concentrations were higher among control patients (179 ± 21 mg/dl) than among treated patients (146 ± 12 mg/dl) throughout the protocol (p = 0.03). One patient in the control group required treatment for a glucose concentration of 63 mg/dl on Day 13 during transition to enteral feeding. Similarly, two IGF-I-treated patients received a dextrose bolus on Day 13 while receiving enteral nutrition. Patients had no symptoms of hypoglycemia; low blood sugar concentrations were identified by protocol-driven glucose monitoring. Serum insulin concentrations were elevated in both groups. There was no difference in insulin dose or in the number of patients treated with insulin between the groups. The C-peptide values were increased for all patients in both groups, but the differences were not statistically significant.

Serum IGF-I Concentrations

At baseline, endogenous serum IGF-I concentrations were below reported physiological concentrations (150-400 ng/ml) for all patients (Fig. 4).[31] Concentrations of IGF-I above 150 ng/ml were achieved for
all treated patients but for only six control patients (p < 0.01). Physiological concentrations were restored for all treated patients within the first 24 hours of dosing. The average time for restoration of physiological levels in the control group was significantly delayed to 7 ± 4.5 days (p < 0.01).

Fig. 4. Bar graph showing serum concentrations of IGF-I from baseline through the second week of treatment. Serum concentrations of IGF-I were depressed below 150 ng/ml after TBI. Administration of IGF-I restored physiological concentrations within 24 hours of dosing. The average concentration of IGF-I in Week 1 was 85 ± 45 ng/ml in the control group and 288 ± 138.5 ng/ml in the treated group (p = 0.001). During the 2nd week after injury, the control patients had an average serum concentration of 130 ± 79.5 ng/ml, compared to 246 ± 143 ng/ml in the treated group (p = 0.02).

The average IGF-I concentrations at Week 1 and Week 2 in the control group were significantly lower than that of the IGF-I-treated group (Fig. 4; p = 0.0001 at Week 1; p = 0.02 at Week 2). The average peak concentration for IGF-I-treated patients was 458 ± 178 ng/ml, compared with 156 ± 99.7 ng/ml for control patients (p < 0.01). The time to peak concentration was 4 ± 2.3 days for treated patients, compared to 11 ± 4.5 days for control patients (p < 0.01). For 13 IGF-I-treated patients, IGF binding protein (BP)-3 concentrations decreased from 2.8 ± 0.2 to 2.1 ± 0.2 mg/dl. Concentrations of IGFBP-2 increased from 275 ± 46 µg/ml to 678 ± 145 µg/ml over the 14-day period. Plasma growth hormone concentrations declined from 2.3 ± 0.6 µg/L to 0.4 ± 0.1 µg/L.

Serum IGF-I concentrations of 350 ng/ml were reached for 11 treated patients during the study; for eight of these patients, this level was achieved during the first 24 hours of infusion. Despite continuous drug administration, serum IGF-I concentrations greater than 350 ng/ml were maintained only for an average of 7.5 ± 3.8 days. For six treated patients, serum IGF-I concentrations did not reach peaks greater than 350 ng/ml at any point in the dosing period; two of these treated patients and three control patients died within the 1st week of injury. The baseline predose concentration of IGF-I was higher for patients whose
serum IGF-I concentrations were above 350 ng/ml during the infusion (80 ± 50 ng/ml vs. 40 ± 8.9 ng/ml, p < 0.05).

Neurological Outcome

After randomization, the 6-hour postinjury score of one patient had improved to 12 before dosing; data from this patient are not included in the neurological outcome analysis. Three deaths occurred in the treated group and five in the control group. Within the 1st week, two patients in the IGF-I-treated group and three in the control group died. Early deaths were due to severe brain injury in three cases, sepsis in one case, and multiple organ dysfunction syndrome in one other case. A favorable outcome trend was observed for treated patients surviving the 1st week after injury with GCS scores of 5 to 7 (Fig. 5). Dichotomized GOS scores improved from poor to good for eight (67%) of 12 treated patients, compared to three (27%) of 11 control patients (p = 0.06).

![Fig. 5. Bar graph showing patient outcome as it relates to admission GCS score. All surviving patients admitted with a GCS score of 4 remained vegetative or severely disabled (according to GOS scores). For eight patients in the treated group and three patients in the control group admitted with GCS scores of 5 through 7, GOS scores improved from poor outcome at Day 15 to moderate disability or good recovery (p = 0.06). Patients with admission GCS scores of 8 through 10 had 15-day GOS scores of good, except for one of the control patients whose GOS score improved from vegetative to good recovery at 6]
months.

The effect of serum IGF-I concentration on the outcome of patients was evaluated. Baseline IGF-I concentrations were not significantly different between survivors (84 ± 48 ng/ml) and nonsurvivors (55 ± 32 ng/ml). No deaths were reported among the 11 patients who achieved serum IGF-I concentrations greater than 350 ng/ml, compared with three deaths among the five patients who did not achieve this concentration (p = 0.02). In the treated group, eight of 11 patients with serum IGF-I concentrations greater than 350 ng/ml achieved moderate-to-good outcome scores at 6 months, compared with only one of five patients with lower concentrations (p < 0.05).

**DISCUSSION**

Head-injured patients treated with IGF-I gained weight and retained nitrogen despite a negative caloric balance and lower nitrogen intake. Previous investigations have demonstrated hypercatabolism and protein loss to be unresponsive despite protein replacement at doses up to 2.5 g/kg/day for severely stressed patients.[6,13,63] Low IGF-I concentrations may contribute to the inefficient use of exogenous protein after head injury.[12,46] All head-injured patients had depressed baseline IGF-I concentrations, and these depressed concentrations persisted for approximately 7 days in the control group. In contrast, administration of IGF-I restored serum concentrations to at least 150 ng/ml for all treated patients within the first 24 hours of dosing. Improved nitrogen balance occurred when IGF-I concentrations were restored to the physiological range. In the current study, the control patients had greater nitrogen output over the study period than the treated patients, despite higher protein intake. Nitrogen retention appeared to be more efficient in the treatment group. The poor caloric intake may have limited the efficacy of IGF-I during the 2nd week; however, low nitrogen intake makes it difficult to interpret this finding conclusively.[12,46]

Nutritional support has not been effective in reducing nitrogen excretion after TBI.[6,58,64] Therapeutic strategies for overriding the catabolic state have been tried in a variety of populations.[21,35,50,59,60,66] Growth hormone has successfully reduced urinary nitrogen loss in both surgically treated and burn populations.[21,35,50,60,66] This effect of growth hormone was not observed after multiple trauma.[4,55] The variability in growth hormone response after TBI, combined with the side effects of hyperglycemia and fluid retention, may limit its potential for use in traumatic brain injury.[10,37]

Insulin-like growth factor-I mediates many of the anabolic effects of growth hormone.[22,31] Within the liver, the binding of growth hormone to receptors initiates the production of IGF-I and its associated binding proteins.[31] This process is dependent on adequate nutritional intake.[31,46] The IGF-I acts both systemically and locally to suppress protein degradation, increase amino acid uptake, and increase cellular proliferation and differentiation.[22] Severe stress and acute disease alter normal patterns of increased IGF-I in response to nutrients.[8,33] When serum concentrations were increased by administration of systemic IGF-I therapy, protein oxidation was reduced after acute thermal injury.[11] Similarly, when physiological concentrations of IGF-I were restored in our head-injured patients receiving IGF-I, nitrogen excretion was lower than that in the control group. The association of reduced nitrogen excretion with IGF-I therapy deserves additional research.

The hypoglycemic effect of IGF-I may be particularly attractive during administration of specialized nutritional support. Previous investigations of TBI have demonstrated higher mortality rates when patients were significantly underfed.[52] Improved neurological outcome was seen when adequate
nutritional support was implemented early.[64] Although nutrition protocols were standardized and initiated early in our study, nutrient intake was lower in the treated group. Despite the compromise in intake, the positive trends continued in the treatment group.

The glucose-modulating properties of IGF-I may contribute to its potential beneficial effect in the treatment of patients with TBI. Hyperglycemia is common after TBI and is associated with poor outcome.[40,54,62] The hypoglycemic potential of IGF-I could contribute to a neurological benefit for patients with TBI.[29] Serum glucose concentrations were significantly lower among our patients treated with IGF-I. This clinical response is similar to observations among other IGF-I-treated populations, but the difference in caloric intake may also have contributed to this observation.

Concentrations of IGF-I may influence mortality after TBI.[27] Gottardis, et al.,[27] observed that patients with TBI who died had lower IGF-I concentrations than survivors. In our study, admission IGF-I concentrations did not predict survival for our patients. However, rapid restoration of physiological IGF-I concentrations for the treated group may explain the different clinical outcomes. The significant difference in the number of deaths between treated patients with IGF-I concentrations above 350 ng/ml and those with lower concentrations suggests that more definitive studies are needed.

Treated patients with admission GCS[57] scores of 5 to 7 who survived the initial week after injury had improved neurological outcomes compared with similar patients in the control group. In the treated group, patients with serum concentrations exceeding 350 ng/ml during the dosing phase had a greater improvement in neurological outcome scores at 6 months. The concentration of 350 ng/ml is near the upper limit of reported normal values and may indicate a minimum concentration for therapeutic efficacy. The full extent of the effects of IGF-I at higher concentrations for extended periods is not known.

Despite continuous infusion, serum concentrations greater than 350 ng/ml could not be maintained throughout the 14-day dosing period. A change in IGF-I clearance would be consistent with the negative feedback of IGF-I on growth hormone secretion.[5] A decrease in growth hormone alters the production of IGFBP-3, the principal binding protein that prolongs the systemic half-life of IGF-I.[3,5,7] A lower concentration of IGFBP-3, as a result of lower production of endogenous growth hormone, reduces the half-life of IGF-I from approximately 18 hours to only 8 minutes.[30] We measured IGFBP-3, IGFBP-2, and growth hormone in 13 of our IGF-I-treated patients. A decline in IGFBP-3 was observed and found to be associated with falling IGF-I concentrations and rising IGFBP-2 concentrations.[7] Growth hormone concentrations also decreased during IGF-I treatment.[7] Dosing strategies to override this effect will be needed if the relationship of IGF-I concentrations and neurological improvement is to be more definitively evaluated.

Higher serum concentrations may improve bioavailability to the injured brain. Insulin-like growth factor-I receptors have been found throughout the brain and persist throughout the aging process.[1,2,15,17] Separate receptors for IGF-I have been isolated on brain capillaries.[23] The maximum binding of the IGF receptor is approximately fivefold greater than that for the blood-brain barrier insulin receptor.[49] The IGF-I is internalized by isolated brain capillaries, suggesting the presence of a transport system. These findings lead one to speculate that circulating IGF-I may be transported into the brain via these existing systems.

Insulin-like growth factor-I is a growth factor present within the central nervous system.[53] Both neurological and neuroprotective properties have been attributed to IGF-I.[9,18,28,42,56] An increased
expression of IGF-I within the central nervous system has been demonstrated after brain injury.[25] Intraventricular administration of IGF-I in a hypoxic-ischemic animal model reduced central nervous system neuronal loss by more than 80%.[26] Therefore, several factors could be responsible for neurological improvement after the administration of IGF-I.

**CONCLUSIONS**

Several promising investigational therapies have failed to produce improved outcome once tested in large, multicenter trials.[19, 20,36,41,48,65] Additional research will be needed to evaluate the potential of IGF-I as a therapeutic agent for patients with head injury. In this small pilot study, significant trends in improved outcome and nutritional response were observed despite the limitation in population size and difference in nutrient intakes. Modified dosing strategies should be tested for a larger population of patients with TBI to clarify the potential of IGF-I for improving neurological outcome. Evidence from normal volunteers and cachectic patients with acquired immune deficiency indicates that growth hormone-dependent binding proteins need to be restored along with IGF-I to optimize serum concentrations and promote anabolism.[36,39] Defining optimal serum and cerebrospinal fluid concentrations and determining a dosing strategy for maintaining those concentrations will be the goals of further investigations using this therapy.

**References**


42. Masters BA, Raizada MK: Insulin-like growth factor I receptors and IGF-I actions in neuronal cultures from the brain. Ann NY Acad Sci 692:89-101, 1993


57. Teasdale G, Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet


Manuscript received June 18, 1996.

Accepted in final form December 20, 1996.

This project was supported by Genentech Protocol No. F0186g and by National Institutes of Health Grant No. M01RR02602.

Address reprint requests to: Jimmi Hatton, Pharm.D., Department of Pharmacy, C-117, University of Kentucky Chandler Medical Center, 800 Rose Street, Lexington, Kentucky 40536-0084.

Click here to view Commentary on this Clinical Pearl.